Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
In November 2024, Health Canada approved Wegovy to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and a BMI of 27 or higher, based on the SELECT trial
Semaglutide is an injectable medication that has shown significant success in assisting individuals with weight loss
Manufacturer savings programs Both Novo Nordisk (maker of Wegovy and Ozempic) and Eli Lilly (maker of Zepbound and Mounjaro) offer savings programs that can reduce out-of-pocket costs for eligible patients
A 2025 systematic review on PubMed associated SARMs with endogenous testosterone suppression (Vasireddi et al., 2025)
If the answer to any of these raises concerns, a fresh vial may be warranted
US$ 22.74
US$ 20.71
US$ 29.90
US$ 21.64
US$ 29.86
US$ 26.19
US$ 24.24
US$ 24.61
